Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema

(2016) Stanley S. Schwartz et al.   DIABETES CARE

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY

(2016) Alan J. Garber et al.   Endocrine Practice

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

(2016) Walter N. Kernan et al.   NEW ENGLAND JOURNAL OF MEDICINE

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015

(2015) Yehuda Handelsman et al.   Endocrine Practice

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus

(2015) Bindu Chamarthi et al.   Journal of Diabetes Research

Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

(2015) Erin D. Roe et al.   Journal of Diabetes Research

Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome

(2015) Alicia A. Thorp et al.   Journal of Diabetes Research

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial

(2014) Arijit Ghosh et al.   INDIAN JOURNAL OF PHARMACOLOGY

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

(2014) Michael Ezrokhi et al.   Diabetology & Metabolic Syndrome

Potential role of renal sympathetic denervation for the treatment of cardiac arrhythmias

(2014) Christian Ukena et al.   EuroIntervention

Variations in 7-day/24-h circadian pattern of ambulatory blood pressure and heart rate of type 2 diabetes patients

(2014) Shipra Bhardwaj et al.   Journal of Diabetes Investigation

Circadian control of glucose metabolism

(2014) Andries Kalsbeek et al.   Molecular Metabolism

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

Economic Costs of Diabetes in the U.S. in 2012

(2013)   DIABETES CARE

The Role of Bromocriptine-QR in the Management of Type 2 Diabetes Expert Panel Recommendations

(2013) Alan Garber et al.   Endocrine Practice

The Necessity for Clinical Reasoning in the Era of Evidence-Based Medicine

(2013) Allan D. Sniderman et al.   MAYO CLINIC PROCEEDINGS

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

(2013) J. Michael Gaziano et al.   Journal of the American Heart Association

Quick release bromocriptine (Cycloset™) a novel treatment for type 2 diabetes also demonstrates improvements in blood pressure

(2012) R. Scranton et al.   Canadian Journal of Diabetes

The Suprachiasmatic Nucleus Controls Circadian Energy Metabolism and Hepatic Insulin Sensitivity

(2012) C. P. Coomans et al.   DIABETES

Neuroadrenergic Dysfunction Along the Diabetes Continuum: A Comparative Study in Obese Metabolic Syndrome Subjects

(2012) N. E. Straznicky et al.   DIABETES

Effect of Bromocriptine-QR on Glycemic Control in Subjects with Uncontrolled Hyperglycemia on One or Two Oral Anti-Diabetes Agents

(2012) Aaron Vinik et al.   Endocrine Practice

Dopamine-Mediated Autocrine Inhibitory Circuit Regulating Human Insulin Secretionin Vitro

(2012) Norman Simpson et al.   MOLECULAR ENDOCRINOLOGY

Patient-Centered Medicine

(2011) Harlan M. Krumholz  

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes

(2011) R. A. DeFronzo   DIABETES CARE

Diagnosis and Classification of Diabetes Mellitus

(2011)   DIABETES CARE

Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

(2011) Ralph A. DeFronzo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Exenatide Plus Rosiglitazone on  -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

(2010) R. A. DeFronzo et al.   DIABETES CARE

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

(2010) J. M. Gaziano et al.   DIABETES CARE

Elevated Fasting Plasma Cortisol Is Associated with Ischemic Heart Disease and Its Risk Factors in People with Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study

(2010) Rebecca M. Reynolds et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Increased Sympathetic and Decreased Parasympathetic Activity Rather Than Changes in Hypothalamic-Pituitary-Adrenal Axis Activity Is Associated with Metabolic Abnormalities

(2010) Carmilla M. M. Licht et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus

(2010) Jeffrey S. Freeman   MAYO CLINIC PROCEEDINGS

Sympathetic nervous activation in obesity and the metabolic syndrome—Causes, consequences and therapeutic implications

(2010) Gavin W. Lambert et al.   PHARMACOLOGY & THERAPEUTICS

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Twenty-eight-day bed rest with hypercortisolemia induces peripheral insulin resistance and increases intramuscular triglycerides

(2009) Melanie G. Cree et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Adverse metabolic and cardiovascular consequences of circadian misalignment

(2009) F. A. J. L. Scheer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA